Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

60275 1492790397HCLSReviewGreeceApril2017.pdf
Energy Boardroom

Kamada slumps on reticence to explain 'positive signal' in AAT trial

19.05.2014 / Scripintelligence

Kamada of Israel believes that despite missing the primary endpoint in a Phase II/III trial, positive secondary endpoint data and results from a recently initiated US Phase II trial will be enough to persuade regulators to approve its inhaled alpha-1…

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: